Post by malati on Jul 18, 2009 16:35:26 GMT -6
Francis Collins a very well mannered and vocal theist has just been appointed to the top job in the NIH, a body which oversees grants on researches in the sciences and medicine not just in U S but in the world. Collins has debated Dawkins in at least 2 debates that I have read and heard.
Nice choice -- very decent and intelligent man.
Article is from the New York Times
Pick to Lead Health Agency Draws Praise and Some Concern
By GARDINER HARRIS
Published: July 8, 2009
Times Topics: Francis S. Collins | National Institutes of Health
Dr. Collins’s selection, which had been rumored for weeks, was praised by top scientists and research advocacy organizations for whom the health institute is a crucial patron.
Based in Bethesda, Md., the N.I.H. is the most important source of research money in the world; over the next 14 months it will dole out about $37 billion in research grants and spend $4 billion on research programs at its Maryland campus.
“Francis Collins is an extraordinary scientist and one of the nicest guys you could ever meet,” said Dr. Otis W. Brawley, chief medical officer of the American Cancer Society.
But praise for Dr. Collins, 59, was not universal or entirely enthusiastic. Dr. Georges C. Benjamin, executive director of the American Public Health Association, called Dr. Collins’s selection a “reasonable choice.” Others privately expressed unease.
There are two basic objections to Dr. Collins. The first is his very public embrace of religion. He wrote a book called “The Language of God,” and he has given many talks and interviews in which he described his conversion to Christianity as a 27-year-old medical student. Religion and genetic research have long had a fraught relationship, and some in the field complain about what they see as Dr. Collins’s evangelism.
The other objection stems from his leadership of the Human Genome Project, which is part of the N.I.H. Although Dr. Collins was widely praised in 2003 when the effort succeeded, the hopes that this discovery would yield an array of promising medical interventions have greatly dimmed, discouraging many.
Dr. Collins cannot be blamed for the unexpected scientific hurdles facing genetic research, but he played an important role in raising expectations impossibly high. In interviews, he called the effort “the most important and the most significant project that humankind has ever mounted” and predicted it would quickly allow everyone to know the genetic risks for many diseases.
Some scientists and advocates for people suffering from diseases criticized the extraordinary amount of money and attention the sequencing effort garnered, saying it distracted from more fruitful areas of research.
Fran Visco, president of the National Breast Cancer Coalition, raised questions about the appointment. “The N.I.H. needs visionary leadership willing to challenge the present stagnation at the institute,” Ms. Visco said. “It may be difficult for Francis, since he has been a part of the system.”
“We look forward to working with him,” she added, “to help him move beyond a focus on technology and to push N.I.H. to foster innovation and regain the sense of urgency to save lives.”
Dr. Collins’s confirmation by the Senate is all but certain. He has long cultivated good relations on Capitol Hill. And since the administration finalized rules for broader use ofstem cells in federal research before nominating him, anti-abortion forces will have a harder time using that issue to stop his confirmation.
Dr. Collins, who resigned last year as director of the National Human Genome Research Institute, would succeed Raynard Kington, who has been acting director at the N.I.H. since last fall.
Dr. Collins earned a Ph.D. in physical chemistry from Yale University and a medical degree from the University of North Carolina. He likes to sing and play a guitar decorated with a double helix, the shape of genetic code.
He was part of a team at the University of Michigan that in 1989 discovered the gene forcystic fibrosis. At the time, many predicted that the discovery would lead to a quick cure. But like so much in genetic research, that hope is still a long way off.
As the leader of the Human Genome Project, Dr. Collins engaged in a fierce public battle with Dr. J. Craig Venter of Celera to finish the sequence first and make it broadly available. The success of Dr. Collins’s project torpedoed much of Celera’s business model. But in a speech last month, Dr. Collins said the N.I.H. needed to form more partnerships with the pharmaceutical industry to create new drugs.
Dr. Alan I. Leshner, chief executive of the American Association for the Advancement of Science, said it was “an excellent idea to have a very credible geneticist heading N.I.H. at a time when we are pursuing so vigorously the promise of personalized medicine based on genomics."
Nice choice -- very decent and intelligent man.
Article is from the New York Times
Pick to Lead Health Agency Draws Praise and Some Concern
By GARDINER HARRIS
Published: July 8, 2009
Times Topics: Francis S. Collins | National Institutes of Health
Dr. Collins’s selection, which had been rumored for weeks, was praised by top scientists and research advocacy organizations for whom the health institute is a crucial patron.
Based in Bethesda, Md., the N.I.H. is the most important source of research money in the world; over the next 14 months it will dole out about $37 billion in research grants and spend $4 billion on research programs at its Maryland campus.
“Francis Collins is an extraordinary scientist and one of the nicest guys you could ever meet,” said Dr. Otis W. Brawley, chief medical officer of the American Cancer Society.
But praise for Dr. Collins, 59, was not universal or entirely enthusiastic. Dr. Georges C. Benjamin, executive director of the American Public Health Association, called Dr. Collins’s selection a “reasonable choice.” Others privately expressed unease.
There are two basic objections to Dr. Collins. The first is his very public embrace of religion. He wrote a book called “The Language of God,” and he has given many talks and interviews in which he described his conversion to Christianity as a 27-year-old medical student. Religion and genetic research have long had a fraught relationship, and some in the field complain about what they see as Dr. Collins’s evangelism.
The other objection stems from his leadership of the Human Genome Project, which is part of the N.I.H. Although Dr. Collins was widely praised in 2003 when the effort succeeded, the hopes that this discovery would yield an array of promising medical interventions have greatly dimmed, discouraging many.
Dr. Collins cannot be blamed for the unexpected scientific hurdles facing genetic research, but he played an important role in raising expectations impossibly high. In interviews, he called the effort “the most important and the most significant project that humankind has ever mounted” and predicted it would quickly allow everyone to know the genetic risks for many diseases.
Some scientists and advocates for people suffering from diseases criticized the extraordinary amount of money and attention the sequencing effort garnered, saying it distracted from more fruitful areas of research.
Fran Visco, president of the National Breast Cancer Coalition, raised questions about the appointment. “The N.I.H. needs visionary leadership willing to challenge the present stagnation at the institute,” Ms. Visco said. “It may be difficult for Francis, since he has been a part of the system.”
“We look forward to working with him,” she added, “to help him move beyond a focus on technology and to push N.I.H. to foster innovation and regain the sense of urgency to save lives.”
Dr. Collins’s confirmation by the Senate is all but certain. He has long cultivated good relations on Capitol Hill. And since the administration finalized rules for broader use ofstem cells in federal research before nominating him, anti-abortion forces will have a harder time using that issue to stop his confirmation.
Dr. Collins, who resigned last year as director of the National Human Genome Research Institute, would succeed Raynard Kington, who has been acting director at the N.I.H. since last fall.
Dr. Collins earned a Ph.D. in physical chemistry from Yale University and a medical degree from the University of North Carolina. He likes to sing and play a guitar decorated with a double helix, the shape of genetic code.
He was part of a team at the University of Michigan that in 1989 discovered the gene forcystic fibrosis. At the time, many predicted that the discovery would lead to a quick cure. But like so much in genetic research, that hope is still a long way off.
As the leader of the Human Genome Project, Dr. Collins engaged in a fierce public battle with Dr. J. Craig Venter of Celera to finish the sequence first and make it broadly available. The success of Dr. Collins’s project torpedoed much of Celera’s business model. But in a speech last month, Dr. Collins said the N.I.H. needed to form more partnerships with the pharmaceutical industry to create new drugs.
Dr. Alan I. Leshner, chief executive of the American Association for the Advancement of Science, said it was “an excellent idea to have a very credible geneticist heading N.I.H. at a time when we are pursuing so vigorously the promise of personalized medicine based on genomics."